14 completed, 5 unknown, 4 terminated, 2 recruiting. 10 Phase 4, 8 Phase 2, 5 Not applicable, 4 Early Phase 1, 3 Phase 3.
Follow Aspirin 81 mg: new trials by email Literature Review of Aspirin 81 mg trials Research Report on Aspirin 81 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Timed Aspirin Chronobiome Study Aspirin 81 mg, Celecoxib 200mg capsule - Healthy | Early Phase 1 | Not yet recruiting | University of Pennsylvania | 60 | 2027-12-01 | 2026-05-29 |
| Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL Aspirin 81 mg, Aspirin 162 mg - Hypertensive Disorders of Pregnancy, Preeclampsia | Phase 4 | Recruiting | Ohio State University | 10742 | 2024-10-18 | 2026-05-04 |
| Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) Statin, Aspirin tablet, Nexlizet - Coronary Artery Disease, Atherosclerosis | Phase 4 | Withdrawn | University of Louisville | 2024-03-01 | 2025-03-17 | |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
| Aspirin and Preeclampsia Aspirin 81 mg, Placebo - Preeclampsia Postpartum | Phase 4 | Recruiting | University of Chicago | 180 | 2021-02-15 | 2026-05-04 |
| Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Aspirin 81 mg, Placebo - Venous Thromboembolism, Postpartum Period | Early Phase 1 | Completed | University of Calgary | 257 | 2020-10-07 | 2023-09-13 |
| Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy) Aspirin 81 mg - Preeclampsia | Completed | Thomas Jefferson University | 130 | 2020-08-21 | 2025-12-02 | |
| Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE) Aspirin 81 mg, Placebo - Pre-Eclampsia, Stage 1 Hypertension | Phase 2 | Terminated | Yale University | 50 | 2020-08-06 | 2023-07-11 |
| COMT on Aspirin Platelets Effects (CAPE) Aspirin 81 mg, Placebo - Cardiovascular Diseases | Phase 4 | Unknown | Brigham and Women's Hospital | 45 | 2020-07-10 | 2021-06-25 |
| The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations Aspirin 81 mg, Vitamin D - COVID, Vitamin D Deficiency | Phase 2 | Withdrawn | Louisiana State University Health Sciences Center in New Orleans | 2020-05-01 | 2021-12-27 | |
| Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81 mg - Coronary Artery Disease, Peripheral Artery Disease | Phase 4 | Unknown | LifeBridge Health | 30 | 2020-01-30 | 2020-10-14 |
| Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease Aspirin 81 mg, Placebo oral tablet - Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 80 | 2019-09-12 | 2024-05-24 |
| Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma Aspirin 81 mg, Aspirin 325mg, Placebo oral tablet - Melanoma (Skin) | Phase 2 | Completed | University of Utah | 95 | 2019-07-25 | 2022-02-18 |
| Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida Aspirin 81 mg, Aspirin 162 mg - Pre-Eclampsia, Hypertension in Pregnancy | Phase 2 / Phase 3 | Completed | The University of Texas Health Science Center, Houston | 220 | 2019-05-06 | 2024-05-08 |
| Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube Aspirin 81 mg - Fallopian Tube Cancer, Fallopian Tube Infection | Early Phase 1 | Active not recruiting | University of Oklahoma | 18 | 2019-03-01 | 2026-02-17 |
| Aspirin for Prevention of Preeclampsia in Healthy, Nulliparous Obese and Overweight Pregnant Women Aspirin 162 mg, Aspirin 81 mg, placebo - Preeclampsia | Not applicable | Unknown | Aswan University Hospital | 600 | 2018-12-01 | 2019-01-10 |
| Aspirin for Prevention of Preeclampsia aspirin 162 mg, aspirin 81 mg, placebo - Preeclampsia | Not applicable | Unknown | Aswan University Hospital | 600 | 2018-12-01 | 2019-01-10 |
| Chronic Kidney Disease (CKD) Platelet Study Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg - Chronic Kidney Diseases, Heart Attack | Phase 3 | Completed | University of Arkansas | 76 | 2018-11-01 | 2022-12-29 |
| Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin Aspirin 81 mg - Aspirin | Not applicable | Completed | Hamilton Health Sciences Corporation | 20 | 2018-03-01 | 2019-09-06 |
| AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study Aspirin 81 mg, Low-molecular-weight heparin - Antiphospholipid Syndrome in Pregnancy, Pregnancy Loss | Early Phase 1 | Terminated | Ottawa Hospital Research Institute | 1 | 2017-11-06 | 2020-04-08 |
Showing 20 of 29. Sign in to see all of them.
Pre-Eclampsia (8) · Coronary Artery Disease (3) · Hypertension (3) · Myocardial Infarction (3) · Acute Coronary Syndrome (2) · Cardiovascular Diseases (2) · Hypertension, Pregnancy-Induced (2) · Melanoma (2) · Venous Thromboembolism (2) · Atherosclerosis (1) · Disseminated Intravascular Coagulation (1) · Fallopian Tube Neoplasms (1) · Hemostatic Disorders (1) · Hyperlipidemias (1) · Ischemic Stroke (1)
Aswan University Hospital (2) · Ottawa Hospital Research Institute (2) · University of Pennsylvania (2) · University of Utah (2) · Brigham and Women's Hospital (1) · Bristol-Myers Squibb (1) · Creighton University (1) · Hamilton Health Sciences Corporation (1) · Johns Hopkins University (1) · LifeBridge Health (1) · Louisiana State University Health Sciences Center in New Orleans (1) · Massachusetts General Hospital (1) · Northwestern University (1) · Ohio State University (1) · Ottawa Heart Institute Research Corporation (1)
United States (21) · Canada (6) · Egypt (2) · France (2) · Netherlands (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Colombia (1) · Croatia (1) · Czechia (1)
Douglas Grossman, MD (2) · Leslie Skeith, MD (2) · Marc Rodger, MD (2) · Aurelien Delluc, MD, PhD (1) · Carsten Skarke, MD (1) · Denise Sholtens, PhD (1) · Derek So, MD (1) · Dinesh Kalra, MD (1) · Dominick J Angiolillo, MD, PhD (1) · Frank H Lau, MD (1) · Garret FitzGerald, MD (1) · Hillart Hosier, MD (1) · Jain Nishank, MD (1)
PMID 22406532, PMID 25035343, PMID 27069632, PMID 29898844, PMID 30883055, PMID 31557056, PMID 31707833, PMID 32129681, PMID 32223444, PMID 32358837, PMID 33461308, PMID 33779986, PMID 35115097, PMID 35172988, PMID 35224730, PMID 35612866, PMID 36067089, PMID 36682595, PMID 37489818, PMID 38502074, PMID 38876331, PMID 39197976, PMID 39238110, PMID 39502066, PMID 39557109, PMID 39827892, PMID 39918467, PMID 40117694, PMID 40875095
2014 (1), K01HL130625 (1), R21HD101127 (1)